Kineta is a privately held emerging biotech company that was founded in 2008. Our mission is to develop novel immuno-therapies that transform patients’ lives. Kineta has established a focused pipeline of life improving therapies that address critical unmet patient needs. We have leveraged our expertise in immunology to advance novel drug development programs in oncology, neuroscience and virology.
